Clinical Trial Update: Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line docetaxel and epirubicin for locally advanced or metastatic adenocarcinoma of the stomach. The study is sponsored by GERCOR.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN